Using the SomaScan® Assay to identify new biomarkers in liver disease
Abstract
In this 1-hour discussion, learn how the SomaScan Assay can be used to detect biomarkers associated with NAFLD—specifically, the identification of circulating proteins associated with fibrosis in NAFLD using a custom 5k-plex SomaScan Assay. Also discussed is the importance of identifying non-invasive biomarkers that improve clinical decision-making and drug development for NAFLD, and the strategies for multiplexed validation of candidate biomarkers discovered using the SomaScan Assay.
Kathleen Corey, MD, MPH, MMSc
Director of the Massachusetts General Hospital NAFLD Program and an assistant professor of medicine at Harvard Medical School
Rebecca Pitts
Principal scientist at the Novartis Institutes for BioMedical Research in Cambridge, Massachusetts
